TY - JOUR
T1 - The role of CD40 in the pathogenesis and treatment of cancer
AU - Eliopoulos, Aristides
AU - Young, Lawrence
PY - 2004/1/1
Y1 - 2004/1/1
N2 - CD40 is a tumour necrosis factor receptor family member that is overexpressed in a broad range of leukaemias, lymphomas and carcinomas, and could contribute to their development. Recent experimental and clinical observations suggest that the CD40 pathway can be exploited for the treatment of malignancy. The mechanisms by which CD40 activation exerts anti-tumour effects include inhibition of tumour cell proliferation, sensitisation to other anti-cancer agents, including cytotoxic drugs, upregulation of immune processing and presentation within the malignant cells, and stimulation of anti-tumour immune responses via activation of dendritic cells. Thus, the CD40 pathway provides an opportunity to muster different anti-cancer approaches in one therapy, and offers an attractive option for future clinical trials.
AB - CD40 is a tumour necrosis factor receptor family member that is overexpressed in a broad range of leukaemias, lymphomas and carcinomas, and could contribute to their development. Recent experimental and clinical observations suggest that the CD40 pathway can be exploited for the treatment of malignancy. The mechanisms by which CD40 activation exerts anti-tumour effects include inhibition of tumour cell proliferation, sensitisation to other anti-cancer agents, including cytotoxic drugs, upregulation of immune processing and presentation within the malignant cells, and stimulation of anti-tumour immune responses via activation of dendritic cells. Thus, the CD40 pathway provides an opportunity to muster different anti-cancer approaches in one therapy, and offers an attractive option for future clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=3343015039&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2004.02.008
DO - 10.1016/j.coph.2004.02.008
M3 - Review article
C2 - 15251129
SN - 1471-4892
VL - 4
SP - 360
EP - 367
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -
